LongBio announced the completion of Series B2 financing, led by Qiming Venture Partners

SHANGHAI, Sept. 24, 2024 /PRNewswire/ -- LongBio Pharma (Suzhou) Co., Ltd. ("LongBio" or the "Company"), a Phase III-stage biotech company focused on the R&D of innovative antibody and fusion protein drugs for allergies and complement-mediated diseases, announced the completion of its Series B2 financing round, raising tens of millions of RMB. The round was led by Qiming Venture Partners, with continued support from existing investors. The funds will primarily be used to advance late-stage clinical studies in the company's pipeline, strengthen team capabilities, and bolster working capital.

Leveraging its proprietary technology platform, LongBio has developed a range of innovative biologics with independent intellectual property rights.